MX2015011753A - Metodos para tratar cancer de vegija. - Google Patents

Metodos para tratar cancer de vegija.

Info

Publication number
MX2015011753A
MX2015011753A MX2015011753A MX2015011753A MX2015011753A MX 2015011753 A MX2015011753 A MX 2015011753A MX 2015011753 A MX2015011753 A MX 2015011753A MX 2015011753 A MX2015011753 A MX 2015011753A MX 2015011753 A MX2015011753 A MX 2015011753A
Authority
MX
Mexico
Prior art keywords
bladder cancer
methods
treating bladder
treating
nanoparticles
Prior art date
Application number
MX2015011753A
Other languages
English (en)
Inventor
Neil P Desai
Original Assignee
Abraxis Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abraxis Bioscience Llc filed Critical Abraxis Bioscience Llc
Publication of MX2015011753A publication Critical patent/MX2015011753A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer

Abstract

La presente invención proporciona métodos y composiciones para el tratamiento de cáncer de vejiga, incluyendo el cáncer de vejiga metastásico y el cáncer de vejiga no invasor de músculo, mediante la administración de una composición que comprende nanopartículas que comprenden un inhibidor de mTOR y, opcionalmente, una albúmina.
MX2015011753A 2013-03-14 2014-03-13 Metodos para tratar cancer de vegija. MX2015011753A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361786175P 2013-03-14 2013-03-14
US201361786167P 2013-03-14 2013-03-14
PCT/US2014/026564 WO2014151853A1 (en) 2013-03-14 2014-03-13 Methods of treating bladder cancer

Publications (1)

Publication Number Publication Date
MX2015011753A true MX2015011753A (es) 2015-12-07

Family

ID=51581053

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015011753A MX2015011753A (es) 2013-03-14 2014-03-13 Metodos para tratar cancer de vegija.

Country Status (17)

Country Link
US (3) US9962373B2 (es)
EP (1) EP2968191B1 (es)
JP (3) JP6309610B2 (es)
KR (1) KR20150127187A (es)
CN (2) CN110934852A (es)
AU (2) AU2014236802B2 (es)
BR (1) BR112015022047A8 (es)
CA (1) CA2903548A1 (es)
ES (1) ES2881851T3 (es)
HK (1) HK1220405A1 (es)
IL (2) IL240983B (es)
MX (1) MX2015011753A (es)
NZ (1) NZ630213A (es)
RU (1) RU2015143490A (es)
SG (1) SG11201507234UA (es)
WO (1) WO2014151853A1 (es)
ZA (1) ZA201506877B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
WO2008076373A1 (en) 2006-12-14 2008-06-26 Abraxis Bioscience, Llc Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
KR101943230B1 (ko) * 2007-03-07 2019-01-28 아브락시스 바이오사이언스, 엘엘씨 항암제로서 라파마이신 및 알부민을 포함하는 나노입자
BRPI1012525A2 (pt) 2009-04-15 2018-07-10 Abraxis Bioscience, Llc. composições de nanopatículas isentas de príons e métodos para sua fabricação
CA2794147A1 (en) 2010-03-29 2011-10-06 Abraxis Bioscience, Llc Use of a composition comprising nanoparticles comprising a taxane and an albumin to improve uptake of chemotherapeutics by tumors and for treating a cancer that is highly fibrotic and/or has a dense stroma
NZ602385A (en) 2010-03-29 2014-08-29 Abraxis Bioscience Llc Methods of treating cancer
CN103140225A (zh) 2010-06-04 2013-06-05 阿布拉科斯生物科学有限公司 治疗胰腺癌的方法
JP6038123B2 (ja) 2011-04-28 2016-12-07 アブラクシス バイオサイエンス， エルエルシー ナノ粒子組成物の脈管内送達およびそれらの使用
PT2790675T (pt) 2011-12-14 2019-09-23 Abraxis Bioscience Llc Utilização de excipientes poliméricos para a liofilização ou a congelação de partículas
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
EP2968254B1 (en) 2013-03-12 2020-04-22 Abraxis BioScience, LLC Methods of treating lung cancer
ES2881851T3 (es) 2013-03-14 2021-11-30 Abraxis Bioscience Llc Métodos para tratar el cáncer de vejiga
LT3233054T (lt) * 2014-12-17 2021-07-26 Pfizer Inc. Pi3k/mtor inhibitoriaus vaisto formos, skirtos intraveniniam įvedimui
EP3699290A1 (en) * 2014-12-24 2020-08-26 F. Hoffmann-La Roche AG Therapeutic, diagnostic, and prognostic methods for cancer
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
WO2016169042A1 (en) * 2015-04-24 2016-10-27 Genedia Biotech Co. Ltd. Combination therapies for bladder cancer
ES2897991T3 (es) 2015-06-29 2022-03-03 Abraxis Bioscience Llc Nanopartículas que comprenden sirolimus y una albúmina para uso en tratamiento de tumores de células epitelioides
JP2018526334A (ja) * 2015-06-29 2018-09-13 アブラクシス バイオサイエンス， エルエルシー ナノ粒子ｍＴＯＲ阻害剤併用治療を使用して血液学的悪性疾患を処置する方法
MX2017016519A (es) * 2015-06-29 2018-08-16 Abraxis Bioscience Llc Biomarcadores para composiciones de nanoparticulas.
MX2017016492A (es) * 2015-06-29 2018-08-16 Abraxis Bioscience Llc Metodos para tratar tumores solidos usando terapia de combinacion de nanoparticula del inhibidor del objetivo mamifero de la rapamicina (mtor).
KR102475256B1 (ko) * 2016-09-28 2022-12-08 아브락시스 바이오사이언스, 엘엘씨 미토콘드리아 및 대사 장애를 치료하는 방법
CN112188892A (zh) 2018-03-20 2021-01-05 阿布拉科斯生物科学有限公司 通过mTOR抑制剂和白蛋白的纳米颗粒的施用治疗中枢神经***障碍的方法
US20220107320A1 (en) 2019-02-15 2022-04-07 Incelldx, Inc. Assaying Bladder-Associated Samples, Identifying and Treating Bladder-Associated Neoplasia, and Kits for Use Therein
CA3133988A1 (en) * 2019-03-19 2020-09-24 Abraxis Bioscience, Llc Subcutaneous administration of nanoparticles comprising an mtor inhibitor and albumin for treatment of diseases
KR20220106758A (ko) 2019-10-28 2022-07-29 아브락시스 바이오사이언스, 엘엘씨 알부민 및 라파마이신의 제약 조성물
TW202123935A (zh) * 2019-11-11 2021-07-01 美商亞伯辛生物科學有限責任公司 用於奈米粒子組合物之生物標記
WO2021258042A1 (en) * 2020-06-19 2021-12-23 Yale University Polymeric bile acid ester nanoparticles comprising an immunomodulator agent to induce antigen-specific tolerance
WO2022006596A1 (en) * 2020-06-30 2022-01-06 Northwestern University A single patient classifier for t1 high grade bladder cancer
WO2024081674A1 (en) 2022-10-11 2024-04-18 Aadi Bioscience, Inc. Combination therapies for the treatment of cancer

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5665383A (en) 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of immunostimulating agents for in vivo delivery
US6528067B1 (en) 1993-02-22 2003-03-04 American Bioscience, Inc. Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
US20030068362A1 (en) 1993-02-22 2003-04-10 American Bioscience, Inc. Methods and formulations for the delivery of pharmacologically active agents
US5997904A (en) 1993-02-22 1999-12-07 American Bioscience, Inc. Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
WO1999000113A1 (en) 1997-06-27 1999-01-07 Vivorx Pharmaceuticals, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5665382A (en) 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of pharmaceutically active agents for in vivo delivery
US5650156A (en) 1993-02-22 1997-07-22 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of nutriceuticals and compositions useful therefor
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
PT693924E (pt) 1993-02-22 2004-09-30 American Biosciences Processos para administracao (in vivo) de substancias biologicas e composicoes utilizadas nestes processos
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US5362478A (en) 1993-03-26 1994-11-08 Vivorx Pharmaceuticals, Inc. Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
US6565842B1 (en) 1995-06-07 2003-05-20 American Bioscience, Inc. Crosslinkable polypeptide compositions
US8137684B2 (en) 1996-10-01 2012-03-20 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030199425A1 (en) 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
WO2000064437A1 (en) 1999-04-22 2000-11-02 American Biosciences, Inc. Long term administration of pharmacologically active agents
EP1178786A4 (en) 1999-05-21 2006-03-01 American Bioscience Inc PHARMACOLOGICALLY ACTIVE PROTEIN STABILIZING AGENTS; METHODS OF MANUFACTURE AND METHODS OF USE
ITMI20001107A1 (it) 2000-05-18 2001-11-18 Acs Dobfar Spa Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel
ITMI20020680A1 (it) 2002-03-29 2003-09-29 Acs Dobfar Spa Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento
ITMI20020681A1 (it) 2002-03-29 2003-09-29 Acs Dobfar Spa Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina
TR200502189T1 (tr) 2002-12-09 2007-01-22 American Bioscience, Inc. Kompozisyonlar ve farmakolojik etken maddelerin aktarımı için yöntemler.
KR20050095826A (ko) 2002-12-09 2005-10-04 아메리칸 바이오사이언스, 인크. 약리학적 물질의 조성물 및 그 전달방법
US20070166388A1 (en) 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
MX2007009960A (es) 2005-02-18 2008-03-11 Abraxis Bioscience Inc Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion.
EP1931321B1 (en) 2005-08-31 2018-12-26 Abraxis BioScience, LLC Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
NZ592132A (en) 2005-08-31 2012-12-21 Abraxis Bioscience Llc Composition comprising nanoparticles of docitaxel and a citrate
US8585753B2 (en) * 2006-03-04 2013-11-19 John James Scanlon Fibrillated biodegradable prosthesis
EP2056812A1 (en) 2006-08-31 2009-05-13 Abraxis BioScience, LLC Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
US20080280987A1 (en) 2006-08-31 2008-11-13 Desai Neil P Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
US20100143340A1 (en) * 2006-12-13 2010-06-10 Schering Corporation Methods and compositions for treating cancer
WO2008076373A1 (en) 2006-12-14 2008-06-26 Abraxis Bioscience, Llc Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
CN101730526A (zh) * 2007-03-07 2010-06-09 阿布拉科斯生物科学有限公司 作为抗癌剂的包含雷帕霉素和白蛋白的纳米颗粒
AU2013204187B2 (en) 2007-03-07 2015-10-01 Abraxis Bioscience, Llc Nanoparticle comprising rapamycin and albumin as anticancer agent
KR101943230B1 (ko) 2007-03-07 2019-01-28 아브락시스 바이오사이언스, 엘엘씨 항암제로서 라파마이신 및 알부민을 포함하는 나노입자
EP3326630A3 (en) 2007-05-03 2018-08-29 Abraxis BioScience, LLC Methods and compositions for treating pulmonary hypertension
CA2689914C (en) 2007-06-01 2016-08-16 Abraxis Bioscience, Llc Use of protein-bound taxane nanoparticles in the treatment of recurrent gynecological cancers
WO2009005673A1 (en) * 2007-06-28 2009-01-08 Schering Corporation Anti-igf1r
MX2010011165A (es) 2008-04-10 2011-02-22 Abraxis Bioscience Llc Composiciones de derivados de taxano hidrofobos y sus usos.
KR20150136137A (ko) 2008-04-10 2015-12-04 아브락시스 바이오사이언스, 엘엘씨 소수성 탁산 유도체의 조성물 및 그의 용도
CA2722992A1 (en) * 2008-05-05 2009-11-12 Schering Corporation Sequential administration of chemotherapeutic agents for treatment of cancer
MX2011006167A (es) 2008-12-11 2011-07-28 Abraxis Bioscience Llc Combinaciones y modos de administracion de agentes terapeuticos y terapia de combinacion.
CA2755121A1 (en) 2009-03-13 2010-09-16 Neil P. Desai Combination therapy with thiocolchicine derivatives
BRPI1014160A2 (pt) 2009-04-10 2015-08-25 Abraxis Bioscience Llc Formulações de nanopartículas e aplicações das mesmas
BRPI1012525A2 (pt) 2009-04-15 2018-07-10 Abraxis Bioscience, Llc. composições de nanopatículas isentas de príons e métodos para sua fabricação
KR20120053052A (ko) * 2009-08-25 2012-05-24 아브락시스 바이오사이언스, 엘엘씨 헤지호그 억제제 및 탁산의 나노입자 조성물로의 조합 요법
JP2013511549A (ja) 2009-11-20 2013-04-04 インフィニティー ファーマシューティカルズ， インコーポレイテッド ヘッジホッグ関連癌の治療のための方法及び組成物
MX359413B (es) 2010-03-26 2018-09-27 Abraxis Bioscience Llc Metodos de tratamiento de carcinoma hepatocelular.
NZ602385A (en) 2010-03-29 2014-08-29 Abraxis Bioscience Llc Methods of treating cancer
CA2794147A1 (en) 2010-03-29 2011-10-06 Abraxis Bioscience, Llc Use of a composition comprising nanoparticles comprising a taxane and an albumin to improve uptake of chemotherapeutics by tumors and for treating a cancer that is highly fibrotic and/or has a dense stroma
NZ708506A (en) 2010-06-02 2016-08-26 Abraxis Bioscience Llc Methods of treating bladder cancer
CN103140225A (zh) 2010-06-04 2013-06-05 阿布拉科斯生物科学有限公司 治疗胰腺癌的方法
MY166014A (en) 2010-06-07 2018-05-21 Abraxis Bioscience Llc Combination therapy methods for treating proliferative diseases
US9636309B2 (en) * 2010-09-09 2017-05-02 Micell Technologies, Inc. Macrolide dosage forms
JP6038123B2 (ja) 2011-04-28 2016-12-07 アブラクシス バイオサイエンス， エルエルシー ナノ粒子組成物の脈管内送達およびそれらの使用
CN103687590A (zh) 2011-04-28 2014-03-26 Stc·Unm公司 用于靶向给药的多孔纳米颗粒支撑脂双层（原始细胞）及其使用方法
PT2790675T (pt) 2011-12-14 2019-09-23 Abraxis Bioscience Llc Utilização de excipientes poliméricos para a liofilização ou a congelação de partículas
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US20140186447A1 (en) 2012-12-28 2014-07-03 Abraxis Bioscience, Llc Nanoparticle compositions of albumin and paclitaxel
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
US20140199404A1 (en) 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on level of a nucleoside transporter
US20140199405A1 (en) 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on mutation status of k-ras
KR102148551B1 (ko) 2013-02-11 2020-08-26 아브락시스 바이오사이언스, 엘엘씨 흑색종을 치료하는 방법
EP2968254B1 (en) 2013-03-12 2020-04-22 Abraxis BioScience, LLC Methods of treating lung cancer
EP2968253A4 (en) 2013-03-13 2016-11-02 Abraxis Bioscience Llc METHODS OF TREATING PEDIATRIC SOLID TUMOR
ES2881851T3 (es) 2013-03-14 2021-11-30 Abraxis Bioscience Llc Métodos para tratar el cáncer de vejiga
WO2015157120A1 (en) 2014-04-06 2015-10-15 Abraxis Bioscience, Llc Combination therapy comprising nanoparticles of a taxane and albumin with abt-263 in methods for treating cancer
US20180064679A1 (en) 2015-03-05 2018-03-08 Abraxis Bioscience, Llc Method for treating cancer based on level of glucocorticoid receptor
MX2017016519A (es) 2015-06-29 2018-08-16 Abraxis Bioscience Llc Biomarcadores para composiciones de nanoparticulas.
MX2017016492A (es) 2015-06-29 2018-08-16 Abraxis Bioscience Llc Metodos para tratar tumores solidos usando terapia de combinacion de nanoparticula del inhibidor del objetivo mamifero de la rapamicina (mtor).
JP2018526334A (ja) 2015-06-29 2018-09-13 アブラクシス バイオサイエンス， エルエルシー ナノ粒子ｍＴＯＲ阻害剤併用治療を使用して血液学的悪性疾患を処置する方法
ES2897991T3 (es) 2015-06-29 2022-03-03 Abraxis Bioscience Llc Nanopartículas que comprenden sirolimus y una albúmina para uso en tratamiento de tumores de células epitelioides
US20170181988A1 (en) 2015-12-23 2017-06-29 Cipla Limited Methods for the treatment of bladder cancer
US20180374583A1 (en) 2017-05-16 2018-12-27 Abraxis Bioscience, Llc Nomogram and survival predictions for pancreatic cancer

Also Published As

Publication number Publication date
US10413531B2 (en) 2019-09-17
EP2968191A1 (en) 2016-01-20
US20180214425A1 (en) 2018-08-02
US9962373B2 (en) 2018-05-08
JP2016513657A (ja) 2016-05-16
ES2881851T3 (es) 2021-11-30
HK1220405A1 (zh) 2017-05-05
RU2015143490A (ru) 2017-04-26
CN110934852A (zh) 2020-03-31
IL240983B (en) 2020-04-30
JP2020050680A (ja) 2020-04-02
WO2014151853A1 (en) 2014-09-25
CA2903548A1 (en) 2014-09-25
NZ630213A (en) 2017-05-26
JP6309610B2 (ja) 2018-04-11
BR112015022047A2 (pt) 2017-07-18
JP2018062531A (ja) 2018-04-19
RU2015143490A3 (es) 2018-03-13
AU2014236802B2 (en) 2019-01-03
ZA201506877B (en) 2017-11-29
AU2014236802A1 (en) 2015-09-24
AU2019201640A1 (en) 2019-04-04
EP2968191B1 (en) 2021-06-16
CN105246468A (zh) 2016-01-13
IL240983A0 (en) 2015-11-30
BR112015022047A8 (pt) 2019-12-10
IL273856A (en) 2020-05-31
US20200138793A1 (en) 2020-05-07
KR20150127187A (ko) 2015-11-16
US20160008330A1 (en) 2016-01-14
SG11201507234UA (en) 2015-10-29
EP2968191A4 (en) 2016-11-16

Similar Documents

Publication Publication Date Title
MX2015011753A (es) Metodos para tratar cancer de vegija.
PH12016502066A1 (en) Methods of treating bladder cancer
MX2021002455A (es) Metodos para tratar tumores de celulas epitelioides.
MX2015011783A (es) Metodos para tratar tumores solidos pediatricos.
MX2015008889A (es) Metodo para tratar cancer con base en el estado de la mutacion k-ras.
HK1213925A1 (zh) 用於治療癌症的涉及抗密蛋白 抗體的組合療法
PH12016500330B1 (en) Certain chemical entities, compositions, and methods
MX2020009223A (es) Anticuerpos anti-fgfr2iiib afucosilados.
MX2015008888A (es) Metodo para tratar el cancer basado en el nivel de un transportador de nucleosido.
EP3060207A4 (en) Methods and compositions for treating cancer
WO2014164704A3 (en) Compounds and compositions for the treatment of cancer
WO2014165090A8 (en) Compounds for the treatment of tuberculosis
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
PH12017501879A1 (en) Methods for treating cancer
EA201492187A1 (ru) Способы лечения солидных опухолей с использованием кофермента q10
PH12016501422A1 (en) Functionalised benzopyran compounds and use thereof
MX2015009818A (es) Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerosis multiple.
EP3079680A4 (en) Compositions and methods for treating, preventing and diagnosing cancer and other proliferative disorders
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
EP3004395A4 (en) Compositions and methods for treating cancer
MX2015013021A (es) 5-bromo-indirrubinas.
MX2016005473A (es) Metodos y composiciones para mejorar la funcion renal.
EP3089745A4 (en) Compounds, compositions, and methods for the treatment of cancers
EP2984185A4 (en) Methods and compositions for treating cancer